Live Soap: Order, Fluctuations and Instabilities in Active Smectics

We construct a hydrodynamic theory of noisy, apolar active smectics, in bulk suspension or on a substrate. Our predictions include: quasi-long-ranged smectic order in dimension d = 2, and long- ranged in d = 3, extending previously published results to all dynamical regimes; Kosterlitz-Thouless melting to an active nematic at high and low concentrations in d = 2; nonzero second-sound speed parallel to the layers; the suppression of giant number fluctuations by smectic elasticity; instability to spontaneous undulation and flow in bulk contractile smectics; a layer spacing instability, possibly oscillatory, for large enough extensile active stresses.Comment: 5 pages, 1 figure, submitted to Phys Rev Let

Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial

Aims  The third Universal Definition of Myocardial Infarction (MI) Task Force classified MIs into five types: Type 1, spontaneous; Type 2, related to oxygen supply/demand imbalance; Type 3, fatal without ascertainment of cardiac biomarkers; Type 4, related to percutaneous coronary intervention; and Type 5, related to coronary artery bypass surgery. Low-density lipoprotein cholesterol (LDL-C) reduction with statins and proprotein convertase subtilisin–kexin Type 9 (PCSK9) inhibitors reduces risk of MI, but less is known about effects on types of MI. ODYSSEY OUTCOMES compared the PCSK9 inhibitor alirocumab with placebo in 18 924 patients with recent acute coronary syndrome (ACS) and elevated LDL-C (≥1.8 mmol/L) despite intensive statin therapy. In a pre-specified analysis, we assessed the effects of alirocumab on types of MI. Methods and results  Median follow-up was 2.8 years. Myocardial infarction types were prospectively adjudicated and classified. Of 1860 total MIs, 1223 (65.8%) were adjudicated as Type 1, 386 (20.8%) as Type 2, and 244 (13.1%) as Type 4. Few events were Type 3 (n = 2) or Type 5 (n = 5). Alirocumab reduced first MIs [hazard ratio (HR) 0.85, 95% confidence interval (CI) 0.77–0.95; P = 0.003], with reductions in both Type 1 (HR 0.87, 95% CI 0.77–0.99; P = 0.032) and Type 2 (0.77, 0.61–0.97; P = 0.025), but not Type 4 MI. Conclusion  After ACS, alirocumab added to intensive statin therapy favourably impacted on Type 1 and 2 MIs. The data indicate for the first time that a lipid-lowering therapy can attenuate the risk of Type 2 MI. Low-density lipoprotein cholesterol reduction below levels achievable with statins is an effective preventive strategy for both MI types.For complete list of authors see http://dx.doi.org/10.1093/eurheartj/ehz299</p

Effect of alirocumab on mortality after acute coronary syndromes. An analysis of the ODYSSEY OUTCOMES randomized clinical trial

Background: Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demonstrated reductions in major adverse cardiovascular events, but not death. We assessed the effects of alirocumab on death after index acute coronary syndrome. Methods: ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) was a double-blind, randomized comparison of alirocumab or placebo in 18 924 patients who had an ACS 1 to 12 months previously and elevated atherogenic lipoproteins despite intensive statin therapy. Alirocumab dose was blindly titrated to target achieved low-density lipoprotein cholesterol (LDL-C) between 25 and 50 mg/dL. We examined the effects of treatment on all-cause death and its components, cardiovascular and noncardiovascular death, with log-rank testing. Joint semiparametric models tested associations between nonfatal cardiovascular events and cardiovascular or noncardiovascular death. Results: Median follow-up was 2.8 years. Death occurred in 334 (3.5%) and 392 (4.1%) patients, respectively, in the alirocumab and placebo groups (hazard ratio [HR], 0.85; 95% CI, 0.73 to 0.98; P=0.03, nominal P value). This resulted from nonsignificantly fewer cardiovascular (240 [2.5%] vs 271 [2.9%]; HR, 0.88; 95% CI, 0.74 to 1.05; P=0.15) and noncardiovascular (94 [1.0%] vs 121 [1.3%]; HR, 0.77; 95% CI, 0.59 to 1.01; P=0.06) deaths with alirocumab. In a prespecified analysis of 8242 patients eligible for ≥3 years follow-up, alirocumab reduced death (HR, 0.78; 95% CI, 0.65 to 0.94; P=0.01). Patients with nonfatal cardiovascular events were at increased risk for cardiovascular and noncardiovascular deaths (P<0.0001 for the associations). Alirocumab reduced total nonfatal cardiovascular events (P<0.001) and thereby may have attenuated the number of cardiovascular and noncardiovascular deaths. A post hoc analysis found that, compared to patients with lower LDL-C, patients with baseline LDL-C ≥100 mg/dL (2.59 mmol/L) had a greater absolute risk of death and a larger mortality benefit from alirocumab (HR, 0.71; 95% CI, 0.56 to 0.90; Pinteraction=0.007). In the alirocumab group, all-cause death declined wit h achieved LDL-C at 4 months of treatment, to a level of approximately 30 mg/dL (adjusted P=0.017 for linear trend). Conclusions: Alirocumab added to intensive statin therapy has the potential to reduce death after acute coronary syndrome, particularly if treatment is maintained for ≥3 years, if baseline LDL-C is ≥100 mg/dL, or if achieved LDL-C is low. Clinical Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01663402

Diffusion of Cadmium Acetate & Self-diffusion of Cadmium Ions in Cadmium Acetate in Agar Gel Medium

808-81

Obstruction Effect & Self-diffusion of Zinc Ion in Agar Gel

1079-108

Effect of Predigestion Process Modifications on VFA Enhancement and Overall Biogas Conversion from Kitchen Solid Waste

574-582The bioprocessing methodology of predigester has been modified to optimize the kitchen solid waste processing for enhanced biogas production. The batch and semi-batch study of bioprocess modification in the predigester by adding Candida sp. to acetogenic predigester culture with controlled aeration (micro-aerobic) has shown the enhancement in volatile fatty acid (VFA) in predigestion. The study of pilot plant which was operated with 24 - 30 days of hydraulic retention time (HRT) with average rate of feeding was 67-82 kg-wet/day. The experiment resulted with average volatile fatty acid (VFA) concentration of 25.41 g/l enhanced from 18.04 g/l in predigestion and ultimately average biogas production increased to 16.23 m3/day from 6.76 m3/day. The efficiency of biogas production per unit feed processed was enhanced from 0.099 m3/kg-wet to 0.2 m3/kg-wet. The present study of waste to energy technology offers a promising decentralized alternative for organic solids/ food waste utilization for enhanced biogas production

<span style="font-size:11.0pt;line-height:115%; font-family:"Calibri","sans-serif";mso-ascii-theme-font:minor-latin;mso-fareast-font-family: "Times New Roman";mso-fareast-theme-font:minor-fareast;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:"Times New Roman";mso-ansi-language:EN-US; mso-fareast-language:EN-US;mso-bidi-language:AR-SA">Preparation of anhydrous FeF₃ by solid state reaction of iron oxide with ammonium hydrogen fluoride</span>

136-138<span style="font-size:11.0pt;line-height:115%; font-family:" calibri","sans-serif";mso-ascii-theme-font:minor-latin;mso-fareast-font-family:="" "times="" new="" roman";mso-fareast-theme-font:minor-fareast;mso-hansi-theme-font:="" minor-latin;mso-bidi-font-family:"times="" roman";mso-ansi-language:en-us;="" mso-fareast-language:en-us;mso-bidi-language:ar-sa"="">The preparation of anhydrous FeF3 has been investigated by solid state reaction of Fe2O3 with NH4HF2. The reaction has been studied in both vertical and horizontal reactors. The difficulties encountered in carrying out the reaction upto 50g charge scale are discussed. The horizontal reactor provides better control of the kinetic factors than the vertical reactor.</span